Terms: = Kidney tumors AND BRIP1, MGC126521, 83990, ENSG00000136492, FANCJ, FLJ90232, Q9BX63, MGC126523, OF AND Prognosis
75 results:
1. Research on texture images and radiomics in urology: a review of urological MR imaging applications.
Valeri A; Nguyen TA
Curr Opin Urol; 2023 Nov; 33(6):428-436. PubMed ID: 37727910
[TBL] [Abstract] [Full Text] [Related]
2. A spectroscopic liquid biopsy for the earlier detection of multiple cancer types.
Cameron JM; Sala A; Antoniou G; Brennan PM; Butler HJ; Conn JJA; Connal S; Curran T; Hegarty MG; McHardy RG; Orringer D; Palmer DS; Smith BR; Baker MJ
Br J Cancer; 2023 Nov; 129(10):1658-1666. PubMed ID: 37717120
[TBL] [Abstract] [Full Text] [Related]
3. Use of genomic markers to improve epidemiologic and clinical research in urology.
Cancel-Tassin G; Koutros S
Curr Opin Urol; 2023 Nov; 33(6):414-420. PubMed ID: 37642472
[TBL] [Abstract] [Full Text] [Related]
4. The role of immunotherapy treatment in non-clear cell renal cell carcinoma: An analysis of the literature.
Ventriglia J; Passarelli A; Pisano C; Cecere SC; Rossetti S; Feroce F; Forte M; Casartelli C; Tambaro R; Pignata S; Perversi F; Di Napoli M
Crit Rev Oncol Hematol; 2023 Aug; 188():104036. PubMed ID: 37263397
[TBL] [Abstract] [Full Text] [Related]
5. Role of the Renin-Angiotensin System Components in Renal Cell Carcinoma: A Literature Review.
Mourão TC; Bezerra SM; Santos VE; Brazão ES; da Costa WH; Zequi SC
Curr Urol Rep; 2023 Jul; 24(7):345-353. PubMed ID: 37074633
[TBL] [Abstract] [Full Text] [Related]
6. Current Status of Predictive Biomarker Development in Metastatic Renal Cell Carcinoma.
Fotia G; Stellato M; Guadalupi V; Sepe P; Claps M; Giannatempo P; Bottiglieri A; Rametta A; Taglialatela I; Vela C; Procopio G; Verzoni E
Curr Oncol Rep; 2023 Jun; 25(6):671-677. PubMed ID: 37000341
[TBL] [Abstract] [Full Text] [Related]
7. Is CRP/Albumin Ratio (CAR) a New Parameter to be Added to Risk Stratification Systems in Metastatic Renal Cell Carcinoma Patients?
Uzun M; Yildirim EC; Ekinci F; Semiz HS
J Coll Physicians Surg Pak; 2022 Nov; 32(11):1425-1429. PubMed ID: 36377009
[TBL] [Abstract] [Full Text] [Related]
8. Clinical significance and oncogenic function of NR1H4 in clear cell renal cell carcinoma.
Huang S; Hou Y; Hu M; Hu J; Liu X
BMC Cancer; 2022 Sep; 22(1):995. PubMed ID: 36123627
[TBL] [Abstract] [Full Text] [Related]
9. Metabolic syndrome, obesity and cancer risk.
Belladelli F; Montorsi F; Martini A
Curr Opin Urol; 2022 Nov; 32(6):594-597. PubMed ID: 36081396
[TBL] [Abstract] [Full Text] [Related]
10. Immune checkpoint inhibitors and kidney disease.
Wang Q; Moledina DG; Sise ME
Curr Opin Nephrol Hypertens; 2022 Sep; 31(5):449-455. PubMed ID: 35894279
[TBL] [Abstract] [Full Text] [Related]
11. [The prognostic value of preoperative neutrophil-to-lymphocyte ratio in patients with non-metastatic renal cell carcinoma].
Chaker K; Ouanes Y; Dali KM; Bibi M; Messaoudi Y; Mosbehi B; Abid K; Sellami A; Ben Rhouma S; Nouira Y
Prog Urol; 2022 Jul; 32(8-9):585-592. PubMed ID: 35606294
[TBL] [Abstract] [Full Text] [Related]
12. Start of a New Era: Management of Non-Clear Cell Renal Cell Carcinoma in 2022.
Maughan BL
Curr Oncol Rep; 2022 Sep; 24(9):1201-1208. PubMed ID: 35438388
[TBL] [Abstract] [Full Text] [Related]
13. Clear Cell Renal Cell Carcinomas with Aggressive Behavior Display Low Intratumor Heterogeneity at the Histological Level.
Manini C; López-Fernández E; Lawrie CH; Laruelle A; Angulo JC; López JI
Curr Urol Rep; 2022 Jun; 23(6):93-97. PubMed ID: 35416538
[TBL] [Abstract] [Full Text] [Related]
14. Evaluation of the Preoperative Haematological Parameters Predicting the High T-Stage and Fuhrman Grade in Renal Cell Carcinoma.
Oner I; Sackan F; Ozdemir D
J Coll Physicians Surg Pak; 2022 Apr; 32(4):461-466. PubMed ID: 35330518
[TBL] [Abstract] [Full Text] [Related]
15. HALP Score as a New Prognostic Index in Metastatic Renal Cell Cancer.
Ekinci F; Balcik OY; Oktay E; Erdogan AP
J Coll Physicians Surg Pak; 2022 Mar; 32(3):313-318. PubMed ID: 35148582
[TBL] [Abstract] [Full Text] [Related]
16. Urological Cancers and kidney Transplantation: a Literature Review.
Hernández-Gaytán CA; Rodríguez-Covarrubias F; Castillejos-Molina RA; Hernández-Porras A; Tobia I; Dubin JM; Autrán-Gómez AM
Curr Urol Rep; 2021 Dec; 22(12):62. PubMed ID: 34913107
[TBL] [Abstract] [Full Text] [Related]
17. Eosinophil counts as a relevant prognostic marker for response to nivolumab in the management of renal cell carcinoma: a retrospective study.
Herrmann T; Ginzac A; Molnar I; Bailly S; Durando X; Mahammedi H
Cancer Med; 2021 Oct; 10(19):6705-6713. PubMed ID: 34405573
[TBL] [Abstract] [Full Text] [Related]
18. The survival outcome of nasopharyngeal cancer patients with traditional Chinese medicine external use: A hospital-based study.
Ku TC; Wang PH; Huang JL; Chen HY; Fang JT; Hsieh HL; Chen JL
J Ethnopharmacol; 2021 Oct; 279():114380. PubMed ID: 34197958
[TBL] [Abstract] [Full Text] [Related]
19. Quality indicators for the management of high-risk upper tract urothelial carcinoma requiring radical nephroureterectomy.
König F; Shariat SF; Karakiewicz PI; Mun DH; Rink M; Pradere B
Curr Opin Urol; 2021 Jul; 31(4):291-296. PubMed ID: 33973537
[TBL] [Abstract] [Full Text] [Related]
20. Renal cell carcinoma pathology in 2021: 'new need for renal cancer immune profiling'.
Sobottka B; Lorch A; Silina K; van den Broek M; Moch H
Curr Opin Urol; 2021 May; 31(3):228-235. PubMed ID: 33742986
[TBL] [Abstract] [Full Text] [Related]
[Next]
